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Abstract
Background: Pancreatic cholesterol esterase has three proposed functions in the intestine: 1) to
control the bioavailability of cholesterol from dietary cholesterol esters; 2) to contribute to
incorporation of cholesterol into mixed micelles; and 3) to aid in transport of free cholesterol to
the enterocyte. Inhibitors of cholesterol esterase are anticipated to limit the absorption of dietary
cholesterol.
Results: The selective and potent cholesterol esterase inhibitor 6-chloro-3-(1-ethyl-2-cyclohexyl)-
2-pyrone (figure 1, structure 1) was administered to hamsters fed a high cholesterol diet
supplemented with radiolabeled cholesterol ester. Hamsters were gavage fed 3H-labeled
cholesteryl oleate along with inhibitor 1, 0–200 micromoles. Twenty-four hours later, hepatic and
serum radioactive cholesterol levels were determined. The ED50 of inhibitor 1 for prevention of
the uptake of labeled cholesterol derived from hydrolysis of labeled cholesteryl oleate was 100
micromoles. The toxicity of inhibitor 1 was investigated in a 30 day feeding trial. Inhibitor 1, 100
micromoles or 200 micromoles per day, was added to chow supplemented with 1% cholesterol
and 0.5% cholic acid. Clinical chemistry urinalysis and tissue histopathology were obtained. No
toxicity differences were noted between control and inhibitor supplemented groups.
Conclusions: Inhibitors of cholesterol esterase may be useful therapeutics for limiting cholesterol
absorption.
Background
Primary hypercholesterolemia is an established risk factor
of atherosclerosis and coronary heart disease (CHD) [1].
Epidemiological data indicate a positive relationship
between serum LDL-cholesterol and CHD, which is the
leading cause of death in both men and women in the
United States. Clinical trials have shown that cholesterol-
lowering regimens are beneficial for prevention of CHD
morbidity and mortality. A variety of regimens are being
used to lower serum cholesterol including diet restriction,
nicotinic acid, bile acid sequestering agents, and HMG-
CoA reductase inhibitors. Reductase inhibitors have
become widely used [2]. Although generally well tolerated
and effective, side effects have been reported in significant
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numbers of participants in controlled trials, including
increases in serum levels of hepatic transaminases,
increases in creatine kinase, muscle weakness, GI distur-
bances, headache, and sleep disorders. With prolonged
use, other side effects have been noted including depres-
sion [3], sensorimotor neuropathy [4], and eczema [5].
Alternative therapies are needed, especially for popula-
tions that cannot tolerate reductase inhibitors
Dietary cholesterol is comprised of free and esterified cho-
lesterol, the ratio depending upon dietary source. In diets
rich in meats, a significant percentage of cholesterol is
esterified. Hydrolysis of cholesterol ester in the lumen of
the small intestine is catalyzed by cholesterol esterase
(CEase), EC3.1.1.13, which liberates free cholesterol. Free
cholesterol mixes with cholesterol contained in bile secre-
tions to form the pool of absorbable cholesterol. Due to
the low solubility of cholesterol, solubilization of choles-
terol by bile salts and lecithin into micelles is essential. In
addition, transport proteins are required to deliver choles-
terol from micelles to the enterocytes for absorption.
CEase provides the hydrolytic activity for hydrolysis of
cholesterol ester and may provide the transport function
for delivery of cholesterol from micelles to enterocytes [6],
although this has not been clearly established [7]. Inhibi-
tors of CEase may provide a method to limit the bioavail-
ability of dietary cholesterol derived from cholesterol
esters and may also limit the absorption of free
cholesterol.
Recently, the feasibility of limiting the bioavailability of
cholesterol derived from cholesterol esters by inhibiting
CEase was reported by Bailey, Gallo and coworkers. Intra-
gastric administration of a single dose of 3-benzyl-6-
chloro-2-pyrone, 2 (figure 1) to rats simultaneous with
feeding of cholesterol ester resulted in a 60% drop in cho-
lesterol absorption, which resulted from a 63% inactiva-
tion of lumenal CEase activity [8]. Compound 2  is a
prototype haloenol lactone developed by Katzenellenbo-
gen and coworkers as an inhibitor of chymotrypsin,
although it is not highly selective [9]. It effectively inhibits
or inactivates numerous serine hydrolases, including
CEase. However, despite its lack of selectivity, compound
2 did provide the opportunity to demonstrate in an ani-
mal study that inhibition of CEase is a new approach to
the treatment of hypercholesterolemia
To circumvent the lack of selectivity of 2, we developed 6-
chloro-3-(1-ethyl-2-cyclohexyl)-2-pyrone, 1 (figure 1) as a
selective and reversible inhibitor of CEase [1]. This
involved replacing the aromatic 3-benzyl group in 2 with
an aliphatic ring tethered to the 3-position. Inhibition of
CEase is very sensitive to the length of the tether. Com-
pound 1 is a potent inhibitor of CEase (Kd = 25 nanomo-
lar) and is highly selective for CEase compared to other
serine hydrolases such as chymotrypsin [10]. Therefore,
compound 1 can now be considered the prototype for
development of selective inhibitors of CEase. In the
present study, we carried out an animal model study of
the effects of 1 on the absorption of cholesterol derived
from cholesteryl oleate to test whether 1 is active in vivo.
Results
Appearance in the serum of free, labeled cholesterol
derived from intestinal hydrolysis of 100 micromoles 3H-
cholesteryl oleate was followed over a 24 hour period.
Absorption occurred in a time-dependent fashion, as
shown in figure 2. The inhibition of uptake of labeled
The selective and potent cholesterol esterase inhibitor 6-chloro-3-(1-ethyl-2-cyclohexyl)-2 pyrone (1) and the prototype  haloenol lactone, 3-benzyl-6-chloro-2-pyrone (2) Figure 1
The selective and potent cholesterol esterase inhibitor 6-chloro-3-(1-ethyl-2-cyclohexyl)-2 pyrone (1) and the prototype 
haloenol lactone, 3-benzyl-6-chloro-2-pyrone (2)
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cholesterol by 100 micromoles of inhibitor 1 was
significant within 6 hours (p < 0.001). Inhibition of
uptake was maximum by 12 hours, and this inhibition
was maintained throughout the 24 hour observation
period, during which time absorption continued in the
control animals. Hepatic levels of labeled cholesterol were
also determined. Hepatic uptake of labeled cholesterol
derived from hydrolysis of 3H-cholesteryl oleate was
apparent within 6 hours, as shown in figure 3, and was
inhibited by administration of 100 micromoles of inhibi-
tor 1 (p < 0.002). Thus, inhibitor 1 is effective at prevent-
ing the hydrolysis of cholesteryl oleate, thereby limiting
the bioavailability of cholesterol derived from cholesterol
esters.
The dose-dependence of inhibitor 1  on the uptake of
labeled cholesterol from hydrolysis of 3H-cholesteryl
oleate was determined. Appearance of cholesterol in
serum and liver was prevented by inhibitor 1 in a dose-
dependent manner, as shown in figures 4a and 4b. Inhib-
itor 1 administered at dosages between 20–200 micro-
moles resulted in an approximate ED50  of 100
micromoles when assessed as a reduction in cholesterol
appearance in both liver and serum.
To investigate the toxic effects of 1, the inhibitor was
administered to animals for 30 days. Animals treated with
inhibitor 1 at 100 and 200 micromoles per day were com-
pared to controls through clinical chemistries, necropsy
and histopathology. There were no differences between
treated and control animals based upon clinical chemis-
tries (liver enzymes and proteins, renal function indices,
and electrolytes). No lesions were noted on necropsy. In
addition, there were no noted differences between treated
and control animals in the histopathology exam (heart,
lung, liver, pancreas, GI tract, thyroid, lymph nodes).
Discussion
There may be additional physiological roles of pancreatic 
cholesterol esterase
CEase is also synthesized in lactating mammary glands
and is secreted into milk in a number of species including
human. Pancreatic and milk CEase are derived from the
same gene [11]. It appears that the same enzyme is present
in serum [12] and is synthesized by human macrophages
[13], eosinophils [14], endothelial cells [15], and liver
[16]. The physiological roles of CEase that is present in
these various locations are not clear, nor is it known
whether inhibitors designed to block hydrolysis of dietary
cholesterol esters through inhibition or inactivation of
CEase in the intestine will have additional biological
effects. It is noteworthy that the lipid-lowering effect of
WAY-121,898, a novel carbamate inhibitor of CEase, was
observed both by oral and by parenteral administration of
the drug [17]. This apparent broad distribution of CEase
expression, however, has been questioned in a recent
report of tissue levels of CEase mRNA in which only pan-
creatic and intestinal tissues were positive [18].
Inhibition of the absorption of cholesterol derived from  intestinal hydrolysis of 3H-cholesteryl oleate was significant  within 6 hours (p < 0.001) in serum in hamsters treated with  100 umole of inhibitor 1 Figure 2
Inhibition of the absorption of cholesterol derived from 
intestinal hydrolysis of 3H-cholesteryl oleate was significant 
within 6 hours (p < 0.001) in serum in hamsters treated with 
100 umole of inhibitor 1. The inhibition continued through-
out the 24 hour observation period (p < 0.0002 at 24 hours)
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Inhibition of hepatic uptake of cholesterol derived from 3H- cholesteryl-oleate in hamsters was also significant within 6  hours (p < 0.002) Figure 3
Inhibition of hepatic uptake of cholesterol derived from 3H-
cholesteryl-oleate in hamsters was also significant within 6 
hours (p < 0.002).
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Cholesterol esterase has a major physiological role in 
cholesterol ester hydrolysis
The major physiological role of CEase in determining the
bioavailability of dietary cholesterol esters is supported by
in vivo studies of CEase inhibitors [8,17,19] and by studies
with CEase gene knockout mice where impaired absorp-
tion of cholesterol ester was observed [7]. Gene knockout
mice, however, did not exhibit impaired absorption of
unesterified cholesterol which suggests that CEase does
not have a direct cholesterol transport function. This con-
clusion differs from the results of a number of studies with
rats in which unesterified cholesterol absorption was
decreased in animals made CEase deficient by removing
pancreatic juice [20] or by treating pancreatic juice with
antibody to CEase [21]. CEase increased the absorption of
free cholesterol into cultured Caco-2 cells [22] and into
gut sacs [23], further suggesting a transport role for CEase.
Other studies, however, did not support a role for CEase
in transport of unesterified cholesterol to enterocytes;
uptake of cholesterol by Caco-2 cells has been reported to
be independent of added CEase or of transfection with
CEase cDNA [24,25]. These conflicting reports regarding a
transport function for CEase may reflect structural differ-
ences in the various CEase used in these studies. The C-ter-
mini of CEase possess a consensus proline-rich eleven-
amino acid repeat sequence (PVPPTGDSGAP)n, which
differs among species in the number of repeats, followed
by an extreme C-terminus conserved nine-amino acid
consensus sequence (AQMPVVIGF). The number of
repeats varies from 2–4 in most animals to 16 in human.
These proline-rich repeats allow CEase to bind to mem-
brane-associated heparin, and it has been suggested that
this may facilitate cholesterol transport [26]. However, a
recent clinical trial with CVT-1 (sodium cellulose sulfate),
a potent and specific inhibitor of human CEase that binds
to the heparin binding site on CEase, did not block
absorption of unesterified cholesterol [27], which sug-
gests that CEase does not have a role in transport of free
cholesterol in humans.
Cholesterol esterase appears to have an indirect but 
essential role in absorption of free cholesterol
Recently, a study was reported [28] that may resolve these
conflicting suggestions of a transport role for CEase. It is
known that CEase can also hydrolyze phospholipids [28],
a role normally assigned to pancreatic phospholipase A2
(PLA2) [29]. Biliary secretions include hepatic micelles
consisting of bile salts, cholesterol and lecithin (phos-
phatidyl choline). This bile mixes with dietary lipid in the
proximal part of the small intestine where pancreatic
enzymes including CEase participate. The digestion of die-
tary lipid and the formation of intestinal mixed micelles
containing free cholesterol, biles salts, lecithin and fatty
acids are highly dependent on the emulsifying and deter-
gent properties of the hepatocyte-derived lecithin and bile
salts. Several studies indicate that the lecithin-rich
micelles formed in the intestine are not efficient transport-
ers of cholesterol to the enterocyte unless the lecithin is
hydrolyzed to lysolecithin, a reaction presumed to be cat-
alyzed mainly by PLA2. The recent study that addressed
the conflicting reports concerning a transport role for
CEase indicated that CEase also has a major role in the
hydrolysis of lecithin [28]. Lymphatic recovery of free
cholesterol from cannulated rat duodenum as a lecithin-
Dose response curves of the effects of inhibitor 1 on hepatic and serum absorption of cholesterol derived from hydrolysis of  cholesteryl oleate indicated an approximate ED50 = 100 umoles Figure 4
Dose response curves of the effects of inhibitor 1 on hepatic and serum absorption of cholesterol derived from hydrolysis of 
cholesteryl oleate indicated an approximate ED50 = 100 umoles.
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containing micelle was enhanced by co-administration of
CEase in rats drained of bile and pancreatic juice. In
addition, cholesterol uptake into Caco-2 cells (an entero-
cyte model) from these same micelles was accelerated by
CEase in a dose-dependent manner that depended upon
the catalytic activity of CEase. The acceleration disap-
peared when CEase was inactivated, and the acceleration
in cholesterol uptake by these cells in response to CEase
occurred only when the micelles contained lecithin. If the
lecithin in the micelles was replaced with lysolecithin,
cholesterol uptake was efficient and did not depend upon
CEase or PLA2. This suggests a new model for cholesterol
absorption (figure 5) with a dual role for CEase. In this
model, CEase does not have a direct transport role in the
absorption of free cholesterol but rather has an indirect
role by virtue of its participation with PLA2 in the
formation of lysolecithin-containing micelles. In this
model, therefore, inhibitors of the catalytic activity of
CEase, such as inhibitor 1, would be expected to limit the
availability of free cholesterol derived from hydrolysis of
dietary cholesterol esters and limit the uptake of free cho-
lesterol by inhibiting the CEase-catalyzed hydrolysis of
lecithin, thereby limiting the formation of lysolecithin-
containing micelles that are the vehicles for efficient deliv-
ery of cholesterol to the enterocytes.
A number of different types of inhibitors of cholesterol 
esterase have been developed
Numerous types of chemicals have been studied as either
mechanism-based or reversible inhibitors of CEase,
including boronic and borinic acids, arylhaloketones, aryl
phosphates and phosphonates, and aryl and cholesteryl
carbamates [30,31]. Application of carbamate chemistry
has been especially useful for development of structure-
activity relationships (SAR). Carbamates are transient
inhibitors (pseudosubstrate inhibitors) of CEase in which
Inhibitors of pancreatic cholesterol esterase have the potential to modify cholesterol metabolism at multiple sites Figure 5
Inhibitors of pancreatic cholesterol esterase have the potential to modify cholesterol metabolism at multiple sites. In this 
model, cholesterol esterase is proposed to contribute to the availability of free cholesterol by catalyzing the hydrolysis of cho-
lesterol esters and contribute to the formation of lysolecithin-containing micelles, which are the vehicles for efficient absorp-
tion of cholesterol, by catalyzing the hydrolysis of lecithin.
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the acylation (carbamoylation) step is followed by a
slower deacylation step. SAR can be developed for the
individual steps of binding, acylation and deacylation. It
has been suggested from studies of carbamates that bile
salts increase the hydrophobicity of both the fatty acid
and cholesterol binding sites of CEase [32]. 6-Chloro-2-
pyrones, which were developed as inhibitors of serine
proteases, have the potential (figure 6) to function as 1)
substrates; 2) pseudosubstrate inhibitors; 3) suicide
inhibitors; 4) reversible inhibitors; or 5) inactivators. Ini-
tial studies of the inhibition of chymotrypsin by 3-benzyl-
6-chloro-2-pyrone were interpreted as demonstrating sui-
cide inhibition [33]. Subsequent studies indicated that
this pyrone is a pseudosubstrate inhibitor in which acyla-
tion is much faster than deacylation such that the acylen-
zyme accumulates and rearranges to the acid chloride,
Substituted 6-chloro-2-pyrones can function as (1) pseudosubstrates of serine hydrolases in which the acylenzyme intermedi- tate B accumulates; (2) suicide inhibitors in which formation of B is followed by attack of an active site nucleophile to form C  and deacyclation to form D; (3) simple substrates in which the reactive acylchloride B hydrolyzes to acylenzyme E followed by  deacylation to regenerate active enzyme F with liberation of the substituted glutaconic acid product Figure 6
Substituted 6-chloro-2-pyrones can function as (1) pseudosubstrates of serine hydrolases in which the acylenzyme intermedi-
tate B accumulates; (2) suicide inhibitors in which formation of B is followed by attack of an active site nucleophile to form C 
and deacyclation to form D; (3) simple substrates in which the reactive acylchloride B hydrolyzes to acylenzyme E followed by 
deacylation to regenerate active enzyme F with liberation of the substituted glutaconic acid product. Alternatively, substituted 
6-chloro-2-pyrones can be simple reversible inhibitors or irreversible active site inhibitors where an active site nucleophile 
attacks the 6-postion of the pyrone with release of chloride.
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which hydrolyzes while tethered to the active site serine,
followed by slow hydrolysis and release of product [34].
This interpretation was supported by crystallographic
analysis of the acylenzyme [35]. By comparison, treat-
ment of chymotrypsin with 5-benzyl-6-chloro-2-pyrone
led to inactivation, in which the active site serine was cov-
alently attached to the 6-position of an intact pyrone, with
loss of chloride. Other related studies of inhibition of ser-
ine proteases by haloenol lactones such as 3-chloroiso-
coumarins and halomethylene furanones have
demonstrated mechanism-based (suicide) inactivation
[36,37]. Inhibitor 1 was shown to be a reversible inhibitor
of CEase [10].
Conclusions
In summary, inhibitor 1 was demonstrated to limit the
bioavailability of cholesterol derived from hydrolysis of
cholesterol ester. Inhibitor 1 can be considered a proto-
type of selective inhibitors of CEase that appear to have
low toxicity in vivo. It remains to be demonstrated whether
inhibition of CEase may also limit the absorption of free
cholesterol.
Methods
Animals and diets
All animals were housed and treated in compliance with
the NIH's Guide for the Care and Use of Laboratory
Animals and the Animal Welfare Act. Outbred male
Golden Syrian hamsters, 100–125 gm (Charles River
Labs.), were housed individually. Animals were accli-
mated to a light cycle of 12 hours light, 12 hours dark, for
one week prior to the beginning of any experiment and
randomly assigned to treatment and control groups.
Unless indicated, all animals in the study were fed a cus-
tom prepared rodent diet, AIN76 (ICN Biologicals,
Aurora, Ohio) and water ad libitum. Treatment protocols
consisted of feeding a custom rodent diet containing unla-
beled free cholesterol and cholic acid to which was added
cholesteryl oleate and varying amounts of inhibitor 1.
Diets were provided daily in predetermined amounts cal-
culated to maintain normal growth. The basal composi-
tion of the semipurified hamster diet contained: casein,
20%; DL-methionine, 0.3%; sucrose, 50%; corn starch,
15%; Alphacel, 5%; corn oil, 5%; choline bitartrate, 0.2%;
mineral mix (AIN), 3.5%; vitamin mix (AIN) 1%.
Acute cholesterol absorption measurements
Cholesterol absorption was assessed using a modification
of the method reported by Harwood et al. [38]. Male
Golden Syrian hamsters were fed the custom diet contain-
ing 1% cholesterol and 0.5% cholic acid for three days
and then fasted overnight. The following morning ham-
sters were gavage fed inhibitor 1 at various doses of 0, 20,
40, 80, 120, 160 and 200 micromoles (corresponding to
0 to 48 mg of inhibitor 1), respectively, suspended in a
10% aqueous ethanol solution containing 0.25% methyl-
cellulose and 0.6% Tween-80 as suspending agents. Dos-
ing was 0.5 ml/100 g of body weight. Immediately
thereafter, hamsters received an oral bolus, 1.5 ml/ham-
ster, of vegetable oil containing 3H-labeled cholesteryl
oleate (1 µCi), and unlabeled cholesteryl oleate (15 mg).
The degree of cholesterol absorption was assessed by the
serum and hepatic levels of 3H-cholesterol measured over
the next 24 hours. Hamsters were anesthetized with iso-
flourane and blood was obtained by cardiac puncture for
determination of serum cholesterol. Animals were eutha-
nized, while anesthetized, by exsanguination. At
necropsy, organs including liver, gall bladder, spleen, kid-
neys, heart, lungs, stomach and intestines, testicles, and
the carcass were weighed. Livers were excised and saponi-
fied in 5 ml of 2.5 M KOH for 2 hours at 70°C. Aliquots
(0.2 mL) of the saponified livers were decolorized with
H2O2 (0.2 mL of 30%), neutralized with 3 N HCl (0.2
mL), and then counted in a liquid scintillation counter.
Total hepatic radioactivity was calculated from the radio-
activity in each aliquot after adjusting for the total volume
of the saponified liver. The percent inhibition of choles-
terol absorption was determined by comparing the
hepatic radioactivity in hamsters receiving inhibitor and
hamsters receiving only the vehicle.
Thirty day toxicity study of inhibitor 1
Toxicity data were obtained by monitoring blood chemis-
try values and urine over a 30 day period, using a modi-
fied method reported by DeNinno et al [39]. Male Golden
Syrian hamsters were acclimated for 1 week to eating pow-
dered custom diet. Weights of the animals and food con-
sumption were monitored daily. Three groups of hamsters
were fed the powdered custom diet containing 1% choles-
terol and 0.5% cholic acid. The control group (n = 6) ate
only custom diet for 30 days. One group of 6 hamsters
was given the optimum dose of inhibitor (100 micro-
moles) added to the powdered diet daily for 30 days. The
third group received the powdered diet with 200 micro-
moles of inhibitor for 30 days. Blood and urine samples
were collected every 5 days by chamber induction of
Isoflurane anesthesia, cardiac puncture, and cystocentesis.
At 30 days the hamsters were anesthetized by chamber
induction and euthanized by exsanguination. At
necropsy, organs including liver, gall bladder, spleen, kid-
neys, heart, lungs, stomach and were weighed. A complete
necropsy with histopathology of all organs was carried
out. Saponification of liver tissue was carried out as
described as above. Tubes were mixed and placed at -20°C
for 15 min to enhance precipitation of protein before
addition of 4 ml of hexane. After vigorous vortexing, sam-
ples were centrifuged at 1500 g for 5 min to separate
phases; 3 ml of the hexane phase was evaporated to dry-
ness under N2 before being redissolved in 0.3 mL of 1%
(v/v) Triton X-100 in ethanol. Cholesterol levels were ana-BMC Pharmacology 2004, 4 http://www.biomedcentral.com/1471-2210/4/5
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lyzed using a commercial assay kit. Triplicate 15 uL aliq-
uots were analyzed in 96-well microtiter plates; 0.2 mL of
reagent was added and the plates incubated at room tem-
perature for 1 hr. Absorbance was read at 490 nm using a
microtiter spectrophotometer and compared to a stand-
ard curve to calculate cholesterol mass.
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